California State Teachers Retirement System Has $3.43 Billion Stock Position in Zoetis Inc. $ZTS

California State Teachers Retirement System raised its position in Zoetis Inc. (NYSE:ZTS) by 6,680.3% during the second quarter, Holdings Channel reports. The firm owned 47,745,365 shares of the company’s stock after purchasing an additional 47,041,186 shares during the period. California State Teachers Retirement System owned about 0.12% of Zoetis worth $3,430,982,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Louisiana State Employees Retirement System bought a new position in shares of Zoetis during the 1st quarter worth about $2,542,000. Wealthfront Advisers LLC lifted its holdings in shares of Zoetis by 80.2% in the second quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock valued at $5,469,000 after purchasing an additional 33,873 shares in the last quarter. Deutsche Bank AG boosted its holdings in Zoetis by 19.1% during the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after acquiring an additional 891,921 shares during the last quarter. Pincus Capital Management LP purchased a new position in Zoetis during the fourth quarter worth about $2,109,000. Finally, Pacer Advisors Inc. boosted its stake in shares of Zoetis by 16.7% in the 1st quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock worth $19,572,000 after buying an additional 23,687 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. TD Cowen reduced their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Barclays lowered their price target on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. UBS Group dropped their price objective on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Morgan Stanley set a $85.00 price objective on Zoetis in a report on Friday, August 7th. Finally, Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Zoetis has a consensus rating of “Hold” and a consensus price target of $101.08.

Zoetis Price Performance

Zoetis stock opened at $73.00 on Friday. Zoetis Inc. has a one year low of $71.00 and a one year high of $152.00. The business has a fifty day moving average price of $75.60 and a 200-day moving average price of $92.10. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The firm has a market capitalization of $30.16 billion, a P/E ratio of 12.03, a PEG ratio of 1.71 and a beta of 0.73.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The company had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the previous year, the business earned $1.76 earnings per share. The firm’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.2 EPS for the current year.

Zoetis Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.